Sign Out
Rheumatoid arthritis: Baricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Baricitinib may be used as monotherapy or in combination with methotrexate (see Precautions, Interactions and Pharmacology: Pharmacodynamics under Actions for available data on different combinations).
Atopic dermatitis: Baricitinib is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy.
Alopecia areata: Baricitinib is indicated for the treatment of severe alopecia areata in adult patients (see Pharmacology: Pharmacodynamics under Actions).
Juvenile idiopathic arthritis: Baricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic DMARDs: Polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [RF+] or negative [RF-], extended oligoarticular), Enthesitis-related arthritis, and Juvenile psoriatic arthritis.
Baricitinib may be used as monotherapy or in combination with methotrexate.
Continue with Google